S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Laser breakthrough could send stock soaring 2,467% (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Laser breakthrough could send stock soaring 2,467% (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Laser breakthrough could send stock soaring 2,467% (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Laser breakthrough could send stock soaring 2,467% (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Laser breakthrough could send stock soaring 2,467% (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Laser breakthrough could send stock soaring 2,467% (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Laser breakthrough could send stock soaring 2,467% (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Laser breakthrough could send stock soaring 2,467% (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Laser breakthrough could send stock soaring 2,467% (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Laser breakthrough could send stock soaring 2,467% (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Laser breakthrough could send stock soaring 2,467% (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Laser breakthrough could send stock soaring 2,467% (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024

Pliant Therapeutics (PLRX) News Today

$16.43
+0.45 (+2.82%)
(As of 02/23/2024 ET)
SourceHeadline
finance.yahoo.com logoPLRX Mar 2024 10.000 put
finance.yahoo.com - February 23 at 3:00 PM
marketbeat.com logoDeutsche Bank AG Sells 305,083 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX)
marketbeat.com - February 20 at 6:00 AM
morningstar.com logoPliant Therapeutics Inc Ordinary Shares PLRX
morningstar.com - February 18 at 7:15 PM
finance.yahoo.com logoPLRX Mar 2024 25.000 call
finance.yahoo.com - February 18 at 2:14 PM
marketbeat.com logoSilverarc Capital Management LLC Boosts Stock Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX)
marketbeat.com - February 18 at 12:54 PM
marketbeat.com logo330,635 Shares in Pliant Therapeutics, Inc. (NASDAQ:PLRX) Bought by Rhenman & Partners Asset Management AB
marketbeat.com - February 12 at 12:59 PM
marketbeat.com logoBarclays PLC Increases Stock Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX)
marketbeat.com - February 11 at 4:42 AM
marketbeat.com logoPliant Therapeutics (NASDAQ:PLRX) Trading 7.2% Higher
marketbeat.com - February 9 at 3:02 PM
markets.businessinsider.com logoBuy Rating on Pliant Therapeutics: Positive Outlook on Bexotegrast Despite Investor Concerns
markets.businessinsider.com - February 8 at 4:15 PM
marketbeat.com logoPliant Therapeutics, Inc. to Post FY2024 Earnings of ($3.38) Per Share, Leerink Partnrs Forecasts (NASDAQ:PLRX)
marketbeat.com - February 8 at 8:13 AM
marketbeat.com logoPliant Therapeutics, Inc. (NASDAQ:PLRX) Forecasted to Earn Q1 2024 Earnings of ($0.80) Per Share
marketbeat.com - February 7 at 8:05 AM
markets.businessinsider.com logoBuy Rating on Pliant Therapeutics: Promising IPF Drug Outlook Overcomes PSC Concerns
markets.businessinsider.com - February 7 at 4:05 AM
msn.com logoPliant Therapeutics Achieves Success in Liver Disease Trial
msn.com - February 6 at 7:58 AM
markets.businessinsider.com logoHC Wainwright & Co. Maintains Buy Rating for Pliant Therapeutics: Here's What You Need To Know
markets.businessinsider.com - February 5 at 4:56 PM
msn.com logoWhy Is Liver Disease-Focused Pliant Therapeutics Stock Trading Lower Today?
msn.com - February 5 at 4:56 PM
marketbeat.com logoPliant Therapeutics (NASDAQ:PLRX) Price Target Cut to $38.00
marketbeat.com - February 5 at 2:35 PM
msn.com logoPliant updates data from mid-stage trial for lead asset
msn.com - February 5 at 11:56 AM
finance.yahoo.com logoPliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
finance.yahoo.com - February 4 at 5:18 PM
marketbeat.com logoPliant Therapeutics (NASDAQ:PLRX) Trading Down 6.3%
marketbeat.com - February 2 at 1:37 PM
marketbeat.com logoPliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Rating of "Buy" from Analysts
marketbeat.com - February 2 at 1:36 AM
marketbeat.com logoPliant Therapeutics, Inc. (NASDAQ:PLRX) General Counsel Mike Ouimette Sells 5,197 Shares
marketbeat.com - January 19 at 6:34 PM
marketbeat.com logoPliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Rating of "Buy" from Analysts
marketbeat.com - January 8 at 2:36 AM
seekingalpha.com logoPliant Therapeutics: Targeting Idiopathic Pulmonary Fibrosis
seekingalpha.com - January 3 at 12:41 PM
markets.businessinsider.com logoBTIG Keeps Their Buy Rating on Pliant Therapeutics (PLRX)
markets.businessinsider.com - January 3 at 9:49 AM
finance.yahoo.com logoPliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 9:49 AM
markets.businessinsider.com logoRBC Capital Reaffirms Their Buy Rating on Pliant Therapeutics (PLRX)
markets.businessinsider.com - November 17 at 6:57 PM
finance.yahoo.com logoPliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
finance.yahoo.com - November 13 at 9:40 PM
markets.businessinsider.com logoAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Pliant Therapeutics (PLRX) and Landos Biopharma (LABP)
markets.businessinsider.com - November 11 at 5:45 AM
benzinga.com logoPliant Therapeutics Stock (NASDAQ:PLRX), Analyst Ratings, Price Targets, Predictions
benzinga.com - November 10 at 10:36 PM
finance.yahoo.com logoIs a Surprise Coming for Pliant Therapeutics (PLRX) This Earnings Season?
finance.yahoo.com - November 9 at 4:19 PM
finance.yahoo.com logoPliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
finance.yahoo.com - November 9 at 4:19 PM
finance.yahoo.com logoPliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1
finance.yahoo.com - November 6 at 8:40 AM
finance.yahoo.com logoPliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer
finance.yahoo.com - October 31 at 8:31 PM
finance.yahoo.com logoPliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
finance.yahoo.com - October 19 at 12:37 PM
finance.yahoo.com logoPliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer
finance.yahoo.com - October 16 at 8:40 PM
finance.yahoo.com logoPliant Therapeutics, Inc. (PLRX) Soars 14.3%: Is Further Upside Left in the Stock?
finance.yahoo.com - September 27 at 1:08 PM
finance.yahoo.com logoPliant (PLRX) Up on Success of Mid-Stage Liver Disease Study
finance.yahoo.com - September 27 at 1:08 PM
marketbeat.com logoPliant Therapeutics (NASDAQ:PLRX) Given "Buy" Rating at Needham & Company LLC
marketbeat.com - September 27 at 8:13 AM
markets.businessinsider.com logoPromising Interim Results from Pliant Therapeutics’ INTEGRIS-PSC Study Bolster Buy Rating
markets.businessinsider.com - September 27 at 8:07 AM
markets.businessinsider.com logoPliant Therapeutics Reveals Encouraging Data From Liver Disease Trial
markets.businessinsider.com - September 26 at 8:06 PM
markets.businessinsider.com logoPliant Therapeutics: Bexotegrast INTEGRIS-PSC Interim Data Surpasses Expectations
markets.businessinsider.com - September 26 at 3:01 PM
msn.com logoPliant Therapeutics' Multi-Pronged Fibrosis Play
msn.com - September 26 at 3:01 PM
finance.yahoo.com logoWhy Shares of Pliant Therapeutics Are Rising Tuesday
finance.yahoo.com - September 26 at 3:01 PM
finance.yahoo.com logoRebel's Edge - September 26: $IMVT, $PLRX, $UNFI, and The PAC12
finance.yahoo.com - September 26 at 3:01 PM
finance.yahoo.com logoPliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
finance.yahoo.com - September 26 at 8:32 AM
markets.businessinsider.com logoAnalysts Are Bullish on Top Healthcare Stocks: Pliant Therapeutics (PLRX), Simulations Plus (SLP)
markets.businessinsider.com - September 25 at 8:46 PM
finance.yahoo.com logoPliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis
finance.yahoo.com - September 25 at 8:46 PM
marketbeat.com logoPliant Therapeutics' (PLRX) "Buy" Rating Reiterated at Needham & Company LLC
marketbeat.com - September 15 at 1:29 PM
finance.yahoo.com logoPliant Therapeutics Appoints Minnie Kuo as Chief Development Officer
finance.yahoo.com - September 15 at 9:03 AM
seekingalpha.com logoIn Therapeutics Space, I Prefer Vicore Pharma Over Pliant Therapeutics
seekingalpha.com - September 15 at 9:00 AM
Get Pliant Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter.



PLRX Media Mentions By Week

PLRX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PLRX
News Sentiment

1.03

0.45

Average
Medical
News Sentiment

PLRX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PLRX Articles
This Week

5

2

PLRX Articles
Average Week

Get Pliant Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:PLRX) was last updated on 2/24/2024 by MarketBeat.com Staff